ZA938421B - Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders - Google Patents
Quinuclidine derivative for treatment of inflammatory and gastrointestinal disordersInfo
- Publication number
- ZA938421B ZA938421B ZA938421A ZA938421A ZA938421B ZA 938421 B ZA938421 B ZA 938421B ZA 938421 A ZA938421 A ZA 938421A ZA 938421 A ZA938421 A ZA 938421A ZA 938421 B ZA938421 B ZA 938421B
- Authority
- ZA
- South Africa
- Prior art keywords
- pct
- treatment
- inflammatory
- gastrointestinal disorders
- quinuclidine derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97524492A | 1992-11-12 | 1992-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA938421B true ZA938421B (en) | 1995-05-11 |
Family
ID=25522825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA938421A ZA938421B (en) | 1992-11-12 | 1993-11-11 | Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders |
Country Status (19)
Country | Link |
---|---|
US (1) | US5886009A (ja) |
EP (1) | EP0668863B1 (ja) |
JP (1) | JP2668164B2 (ja) |
KR (1) | KR950704311A (ja) |
CN (1) | CN1034732C (ja) |
AT (1) | ATE147385T1 (ja) |
AU (1) | AU676489B2 (ja) |
CA (1) | CA2149242C (ja) |
DE (1) | DE69307340T2 (ja) |
DK (1) | DK0668863T3 (ja) |
ES (1) | ES2096312T3 (ja) |
FI (1) | FI934983A (ja) |
GR (1) | GR3022459T3 (ja) |
IL (1) | IL107495A (ja) |
MX (1) | MX9307062A (ja) |
MY (1) | MY130145A (ja) |
NZ (1) | NZ254604A (ja) |
WO (1) | WO1994011368A1 (ja) |
ZA (1) | ZA938421B (ja) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6387925B1 (en) * | 1999-06-01 | 2002-05-14 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions |
US6262067B1 (en) * | 1999-06-22 | 2001-07-17 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions |
DE10001785A1 (de) * | 2000-01-18 | 2001-07-19 | Boehringer Ingelheim Pharma | NK¶1¶-Rezeptor-Antagonisten zur Behandlung des Restless Legs Syndroms |
US6861526B2 (en) | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
DE602004028150D1 (de) * | 2003-11-26 | 2010-08-26 | Pfizer Prod Inc | Aminopyrazolderivate als gsk-3-inhibitoren |
LT1713504T (lt) * | 2004-01-30 | 2017-09-11 | Zoetis Services Llc | Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms |
CA2573271C (en) | 2004-07-15 | 2015-10-06 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
BRPI0613403A2 (pt) | 2005-07-15 | 2009-02-10 | Amr Technology Inc | tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina |
JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
EP2336120B1 (en) | 2007-01-10 | 2014-07-16 | MSD Italia S.r.l. | Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US8598184B2 (en) | 2008-03-03 | 2013-12-03 | Tiger Pharmatech | Protein kinase inhibitors |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用 |
EP2429295B1 (en) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
KR101485645B1 (ko) | 2009-10-14 | 2015-01-22 | 머크 샤프 앤드 돔 코포레이션 | p53 활성을 증가시키는 치환된 피페리딘 및 그의 용도 |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制 |
EP4079856A1 (en) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
EP2900241B1 (en) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
SI2925888T1 (en) | 2012-11-28 | 2018-02-28 | Merck Sharp & Dohme Corp. | Compounds and methods for the treatment of cancer |
RU2690663C2 (ru) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Замещенные имидазопиридины в качестве ингибиторов hdm2 |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
DK0532527T3 (da) * | 1990-06-01 | 1995-01-02 | Pfizer | 3-amino-2-arylquinuclidiner, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse |
DE122006000066I2 (de) * | 1991-05-31 | 2007-12-06 | Pfizer | Chinuclidinderivate |
DK0533280T4 (da) * | 1991-09-20 | 2005-02-28 | Glaxo Group Ltd | Ny medicinsk anvendelse af tachykininantagonister |
US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
-
1993
- 1993-07-19 AU AU46780/93A patent/AU676489B2/en not_active Ceased
- 1993-07-19 ES ES93917176T patent/ES2096312T3/es not_active Expired - Lifetime
- 1993-07-19 DK DK93917176.5T patent/DK0668863T3/da active
- 1993-07-19 EP EP93917176A patent/EP0668863B1/en not_active Expired - Lifetime
- 1993-07-19 JP JP6502707A patent/JP2668164B2/ja not_active Expired - Lifetime
- 1993-07-19 CA CA002149242A patent/CA2149242C/en not_active Expired - Fee Related
- 1993-07-19 AT AT93917176T patent/ATE147385T1/de not_active IP Right Cessation
- 1993-07-19 US US08/500,958 patent/US5886009A/en not_active Expired - Fee Related
- 1993-07-19 WO PCT/US1993/006624 patent/WO1994011368A1/en active IP Right Grant
- 1993-07-19 DE DE69307340T patent/DE69307340T2/de not_active Expired - Fee Related
- 1993-07-19 NZ NZ254604A patent/NZ254604A/en unknown
- 1993-07-19 KR KR1019950701877A patent/KR950704311A/ko not_active Application Discontinuation
- 1993-11-04 IL IL10749593A patent/IL107495A/en not_active IP Right Cessation
- 1993-11-09 MY MYPI93002345A patent/MY130145A/en unknown
- 1993-11-11 ZA ZA938421A patent/ZA938421B/xx unknown
- 1993-11-11 MX MX9307062A patent/MX9307062A/es not_active IP Right Cessation
- 1993-11-11 CN CN93114371A patent/CN1034732C/zh not_active Expired - Fee Related
- 1993-11-11 FI FI934983A patent/FI934983A/fi unknown
-
1997
- 1997-01-31 GR GR970400170T patent/GR3022459T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR950704311A (ko) | 1995-11-17 |
GR3022459T3 (en) | 1997-04-30 |
EP0668863A1 (en) | 1995-08-30 |
CA2149242A1 (en) | 1994-05-26 |
JP2668164B2 (ja) | 1997-10-27 |
CN1091134A (zh) | 1994-08-24 |
CN1034732C (zh) | 1997-04-30 |
FI934983A (fi) | 1994-05-13 |
MX9307062A (es) | 1994-05-31 |
ES2096312T3 (es) | 1997-03-01 |
NZ254604A (en) | 1997-06-24 |
MY130145A (en) | 2007-06-29 |
IL107495A (en) | 1998-12-27 |
DE69307340D1 (de) | 1997-02-20 |
EP0668863B1 (en) | 1997-01-08 |
IL107495A0 (en) | 1994-02-27 |
AU4678093A (en) | 1994-06-08 |
DE69307340T2 (de) | 1997-04-24 |
JPH07508731A (ja) | 1995-09-28 |
ATE147385T1 (de) | 1997-01-15 |
DK0668863T3 (da) | 1997-06-30 |
WO1994011368A1 (en) | 1994-05-26 |
FI934983A0 (fi) | 1993-11-11 |
AU676489B2 (en) | 1997-03-13 |
CA2149242C (en) | 1998-08-04 |
US5886009A (en) | 1999-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL107495A0 (en) | Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders | |
KR100246065B1 (en) | Substituted 3-aminoquinuclidines | |
MY107157A (en) | Quinuclidine derivatives. | |
UA41906C2 (uk) | Спосіб лікування неврологічних порушень, викликаних травмами | |
ATE141792T1 (de) | Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson- syndromen | |
IL114600A0 (en) | Thiazole and thiadiazole compounds their preparation and pharmaceutical composition containing them | |
PL309604A1 (en) | Pharmaceutical composition for treating nicotin dependence | |
EP0779889A4 (en) | PYRAZOLO 3,4-g] QUINOXALINE COMPOUNDS INHIBITING FCDP RECEPTOR PROTEIN TYROSINE KINASE | |
ATE216891T1 (de) | Verwendung von immunosuppressiva zur behandlung der schizophrenie | |
NO951865L (no) | Quinuclidin-derivat som substans-P antagonist |